- Home
- SNES vs BCAB Comparison
SNES vs BCAB Comparison
Compare SNES & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNES | BCAB |
|---|---|---|
| Founded | 2004 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1M | 12.5M |
| IPO Year | 2016 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SNES | BCAB |
|---|---|---|
| Price | $1.77 | $0.16 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 51.8K | ★ 1.4M |
| Earning Date | 03-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.99 | 44.19 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $600,000.00 | $300,000.00 |
| Revenue This Year | $109.77 | N/A |
| Revenue Next Year | $80.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 132.56 | N/A |
| 52 Week Low | $1.30 | $0.13 |
| 52 Week High | $5.99 | $1.43 |
Technical Indicators
Market Signals| Indicator | SNES | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 39.68 | 40.68 |
| Support Level | $1.65 | $0.14 |
| Resistance Level | $2.26 | $0.27 |
| Average True Range (ATR) | 0.19 | 0.02 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 3.75 | 22.52 |
Price Performance
Historical ComparisonAbout SNES SenesTech Inc.
SenesTech Inc is a United States-based biotech platform and research company engaged in developing technology for managing animal pest populations through fertility control. The company provides its solutions to the animal market, commercial markets, and food markets. It currently has two product lines of fertility control products: ContraPest and Evolve.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.